Skip to main
IMNM

Immunome (IMNM) Stock Forecast & Price Target

Immunome (IMNM) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunome is positioned for success in the biotechnology industry with a strong pipeline of promising drugs such as varegacestat and IM-3050 with positive results in Phase 3 and IND clearance. However, the company also faces risks in terms of financials and regulatory hurdles. With a focus on developing targeted oncology therapies and potential expansion into solid tumors, Immunome offers potential for growth in the long-term.

Bears say

Immunome is a biotechnology company focused on developing targeted oncology therapies and has a strong precision-oncology pipeline. Their lead asset, varegacestat, has shown potential as a top inhibitor for desmoid tumors. However, potential legal action due to side effects and financial risks for the company may pose a challenge. The company's combination therapies and preclinical studies show promise, but more research is needed to fully evaluate the effectiveness of their treatments.

Immunome (IMNM) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunome and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunome (IMNM) Forecast

Analysts have given Immunome (IMNM) a Buy based on their latest research and market trends.

According to 12 analysts, Immunome (IMNM) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunome (IMNM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.